派林生物：关于全资子公司获得药物临床试验批准通知书的公告

Group 1 - The core announcement is that Palin Biopharma's wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for a clinical trial of intravenous human immunoglobulin (pH4) after changes in the production process [2] Group 2 - The approval allows Guangdong Shuanglin to proceed with clinical trials, which may enhance the company's product offerings and market position in the biopharmaceutical industry [2]